Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.

David R Boulware, David Seftel

We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.

2021

coronavirus, covid-19, Cohort, SARS-CoV-2, Fluvoxamine

10.1093/ofid/ofab050

Open forum infectious diseases